title: Salvage therapy for relapsed or refractory acute myeloid leukemia.
abstract: There are a significant number of patients diagnosed with acute leukemia who either fail to achieve remission or who relapse thereafter. Challenges in treating this patient population include accurately assessing prognosis of disease and whether remission can be achieved; assessing the ability of patients to tolerate aggressive salvage therapies; choosing a salvage therapy that is most likely to succeed; and identifying suitable patients for hematopoietic stem cell transplantation. Despite the development of a variety of new investigational therapies, relapsed or refractory acute myeloid Leukemia remains a difficult clinical problem. Clinicians will need to consider all currently available approaches, including cytotoxic chemotherapy, targeted agents, and allogeneic stem cell transplantation, to optimize outcomes.
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
authors.forename: James K
authors.initials: JK
authors.lastname: Mangan
authors.forename: Selina M
authors.initials: SM
authors.lastname: Luger
keywords: acute myeloid leukemia; relapsed or refractory; salvage therapy
references.citation: Leuk Lymphoma. 2002 Sep;43(9):1715-27
references.pmid: 12685823
references.citation: Blood. 2009 Apr 23;113(17):3938-46
references.pmid: 19029442
references.citation: Leukemia. 1998 Jul;12(7):1049-55
references.pmid: 9665189
references.citation: Curr Opin Hematol. 1997 Nov;4(6):395-400
references.pmid: 9358995
references.citation: Am J Hematol. 2009 Nov;84(11):733-7
references.pmid: 19806665
references.citation: Clin Cancer Res. 2009 Nov 1;15(21):6732-9
references.pmid: 19843663
references.citation: Blood. 2011 Feb 10;117(6):1828-33
references.pmid: 21051557
references.citation: Cancer. 2010 Nov 1;116(21):5012-21
references.pmid: 20629023
references.citation: Bone Marrow Transplant. 2000 Aug;26(4):397-404
references.pmid: 10982286
references.citation: J Hematol Oncol. 2010 Apr 23;3:17
references.pmid: 20416083
references.citation: Blood. 1994 Apr 15;83(8):2086-92
references.pmid: 7512838
references.citation: Bone Marrow Transplant. 2010 Aug;45(8):1309-15
references.pmid: 20062094
references.citation: Blood. 2009 Jun 25;113(26):6567-71
references.pmid: 19389879
references.citation: J Clin Oncol. 1989 Aug;7(8):1071-80
references.pmid: 2666590
references.citation: Leuk Lymphoma. 1993 Mar;9(4-5):343-50
references.pmid: 8394169
references.citation: Cancer. 2007 Dec 15;110(12):2756-60
references.pmid: 17948909
references.citation: Oncogene. 2007 May 28;26(25):3679-90
references.pmid: 17530021
references.citation: Br J Haematol. 2006 Jul;134(1):58-60
references.pmid: 16803568
references.citation: Ann Hematol. 1999 Aug;78(8):380-4
references.pmid: 10460353
references.citation: Cancer. 2008 Oct 15;113(8):2090-6
references.pmid: 18756533
references.citation: J Clin Oncol. 1985 Jul;3(7):992-7
references.pmid: 3894588
references.citation: J Clin Oncol. 1995 Jan;13(1):11-8
references.pmid: 7799010
references.citation: Blood. 2005 Dec 15;106(13):4261-8
references.pmid: 16150937
references.citation: Blood. 1999 Jun 1;93(11):3678-84
references.pmid: 10339474
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1969-78
references.pmid: 15632409
references.citation: Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444
references.pmid: 20733555
references.citation: J Clin Oncol. 2010 Nov 20;28(33):4919-25
references.pmid: 20956622
references.citation: Leuk Lymphoma. 2010 Feb;51(2):252-60
references.pmid: 20109071
references.citation: Hematology Am Soc Hematol Educ Program. 2006;:178-84
references.pmid: 17124058
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3730-8
references.pmid: 20625136
references.citation: Br J Haematol. 2005 Apr;129(1):18-34
references.pmid: 15801952
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4339-45
references.pmid: 20733134
references.citation: J Clin Oncol. 1988 Feb;6(2):213-7
references.pmid: 3422260
references.citation: Blood. 2011 Mar 24;117(12):3294-301
references.pmid: 21270442
references.citation: Leukemia. 2000 Mar;14(3):476-9
references.pmid: 10720145
references.citation: Leukemia. 1994 Nov;8(11):1847-53
references.pmid: 7967730
references.citation: J Hematol Oncol. 2009 Aug 12;2:36
references.pmid: 19674465
references.citation: Leuk Res. 2010 Jun;34(6):752-6
references.pmid: 19878996
references.citation: Blood. 2006 Aug 1;108(3):1092-9
references.pmid: 16551971
references.citation: Leukemia. 1993 Apr;7(4):549-52
references.pmid: 8464233
references.citation: Br J Haematol. 2010 Jan;148(2):217-25
references.pmid: 19804455
references.citation: Ann Hematol. 2003 Apr;82(4):231-5
references.pmid: 12707726
references.citation: Blood. 2003 Oct 1;102(7):2379-86
references.pmid: 12791647
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5619-25
references.pmid: 18765556
references.citation: Biol Blood Marrow Transplant. 2009 Nov;15(11):1431-8
references.pmid: 19822303
references.citation: Leukemia. 1999 Aug;13(8):1214-20
references.pmid: 10450749
references.citation: Bone Marrow Transplant. 2010 Dec;45(12):1692-8
references.pmid: 20208570
references.citation: Biol Blood Marrow Transplant. 2011 May;17(5):754-8
references.pmid: 20951817
references.citation: Acta Haematol. 2010;124(3):153-9
references.pmid: 20938170